Intellectual Property Expands to 41 Patents in more than 20 Countries
LAKE FOREST, Calif., April 23 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to improve cardiac performance through Aortic Flow Therapy, announced today that the United States Patent and Trademark Office has issued U.S. Patent number 7,331,921 (the '921 patent) entitled "Implantable Heart Assist System and Method of Applying Same." The '921 patent which discloses and claims methods and apparatus for intravascular renal (kidney) perfusion is exclusively owned by Orqis and is the Company's 15th U.S. Patent.
Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "This latest patent is the result of Orqis' aggressive intellectual property strategy to treat the cardio-renal syndrome and improve cardiac performance with less invasive treatment approaches." He continued, "Orqis is developing a large intellectual property footprint that addresses the treatment gap between medical management and more invasive procedures without ever touching the heart."
Orqis' patent portfolio now encompasses 15 U.S. Patents and 26 International Patents in over 20 countries.
About Heart Failure
Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.
About Orqis Medical Corporation
Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.
For more information on Orqis Medical, please visit orqis.com
Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.
|SOURCE Orqis Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved